Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the year ended December 31, 2025 and highlighted recent developments. “The fourth quarter of 2025 was a transformational quarter for the Company as we transitioned to a global pivotal Pha ...